[
  {
    "ts": null,
    "headline": "Will Keytruda Continue to Aid Merck's Top Line in Q4 Earnings?",
    "summary": "Keytruda drives over half of MRK's pharma revenues, but softer Q3 sales put investor focus on whether the blockbuster drug can lift Q4 sales performance.",
    "url": "https://finnhub.io/api/news?id=19b420a6dcda08e7f1429426a51ffa66c23cb562ee2f1217ac826e48545073b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768401300,
      "headline": "Will Keytruda Continue to Aid Merck's Top Line in Q4 Earnings?",
      "id": 138113196,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Keytruda drives over half of MRK's pharma revenues, but softer Q3 sales put investor focus on whether the blockbuster drug can lift Q4 sales performance.",
      "url": "https://finnhub.io/api/news?id=19b420a6dcda08e7f1429426a51ffa66c23cb562ee2f1217ac826e48545073b7"
    }
  },
  {
    "ts": null,
    "headline": "Spherix Global Insights Highlights Evolving PD-1 Landscape as Subcutaneous Use Grows and Biosimilars Approach across Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma",
    "summary": "US Oncologists anticipate rapid biosimilar uptake – up to 50% of PD-1/PD-L1 eligible patients within the first year – while viewing subcutaneous PD-1s as a practical evolution in care delivery more than a major paradigm shift.Exton, PA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights reports new findings from its inaugural Market Dynamix™: PD-1 Inhibition in Solid Tumors (US) study, based on quantitative and qualitative responses from more than 100 U.S. oncologists. The research reveal",
    "url": "https://finnhub.io/api/news?id=23ee66b7a9544b30caf09d6a77fc1fe5552ce480bdf77de4d5bd94e46ebf3349",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768399740,
      "headline": "Spherix Global Insights Highlights Evolving PD-1 Landscape as Subcutaneous Use Grows and Biosimilars Approach across Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma",
      "id": 138111923,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "US Oncologists anticipate rapid biosimilar uptake – up to 50% of PD-1/PD-L1 eligible patients within the first year – while viewing subcutaneous PD-1s as a practical evolution in care delivery more than a major paradigm shift.Exton, PA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights reports new findings from its inaugural Market Dynamix™: PD-1 Inhibition in Solid Tumors (US) study, based on quantitative and qualitative responses from more than 100 U.S. oncologists. The research reveal",
      "url": "https://finnhub.io/api/news?id=23ee66b7a9544b30caf09d6a77fc1fe5552ce480bdf77de4d5bd94e46ebf3349"
    }
  },
  {
    "ts": null,
    "headline": "TetraScience Appoints Matt Studney as Chief Customer Officer, Signaling Industry Shift Toward Platform-Based Scientific AI",
    "summary": "TetraScience, the Scientific Data and AI company, today announced the appointment of Matt Studney as Chief Customer Officer. Studney is a seasoned business, R&D, and technology leader with more than two decades of experience operating at the intersection of science, data, and engineering.",
    "url": "https://finnhub.io/api/news?id=e42bec4fdf49f65b7f836585418db5d2acc03f6899e261b62a7adfdb9e3dea97",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768395600,
      "headline": "TetraScience Appoints Matt Studney as Chief Customer Officer, Signaling Industry Shift Toward Platform-Based Scientific AI",
      "id": 138111214,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "TetraScience, the Scientific Data and AI company, today announced the appointment of Matt Studney as Chief Customer Officer. Studney is a seasoned business, R&D, and technology leader with more than two decades of experience operating at the intersection of science, data, and engineering.",
      "url": "https://finnhub.io/api/news?id=e42bec4fdf49f65b7f836585418db5d2acc03f6899e261b62a7adfdb9e3dea97"
    }
  },
  {
    "ts": null,
    "headline": "XLV Vs. BME: Total Return Or Income, Which Healthcare Strategy Wins?",
    "summary": "Explore why Health Care may mean-revert in 2026. Compare XLV vs BME yields, valuation and NAV discount, plus key risks.",
    "url": "https://finnhub.io/api/news?id=318d9b4b3675a3baea4b15c447112727402dbe4585fb6b8510c5c27f681f97dc",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768394359,
      "headline": "XLV Vs. BME: Total Return Or Income, Which Healthcare Strategy Wins?",
      "id": 138113004,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222153/image_2194222153.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Explore why Health Care may mean-revert in 2026. Compare XLV vs BME yields, valuation and NAV discount, plus key risks.",
      "url": "https://finnhub.io/api/news?id=318d9b4b3675a3baea4b15c447112727402dbe4585fb6b8510c5c27f681f97dc"
    }
  },
  {
    "ts": null,
    "headline": "Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference",
    "summary": "Novo Nordisk's CEO spoke about GLP-1 pricing and Pfizer's CEO spoke about the company's obesity ambitions while at the JPMorgan Healthcare Conference.",
    "url": "https://finnhub.io/api/news?id=d6f8d00d213e88039b110411652e19cc7093e8ec9df7d4de80999607d7c8eb25",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768392531,
      "headline": "Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference",
      "id": 138112555,
      "image": "https://image.cnbcfm.com/api/v1/image/108222573-17624550972025-11-06t184628z_1673660215_rc25rhas1dn5_rtrmadp_0_usa-trump.jpeg?v=1762455130&w=1920&h=1080",
      "related": "MRK",
      "source": "CNBC",
      "summary": "Novo Nordisk's CEO spoke about GLP-1 pricing and Pfizer's CEO spoke about the company's obesity ambitions while at the JPMorgan Healthcare Conference.",
      "url": "https://finnhub.io/api/news?id=d6f8d00d213e88039b110411652e19cc7093e8ec9df7d4de80999607d7c8eb25"
    }
  },
  {
    "ts": null,
    "headline": "[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global T-Cell Engagers Market size & share revenue was valued at approximately USD 2.4 Billion in 2024 and is expected to reach USD 2.5 Billion in 2025 and is expected to reach around USD 18.8 Billion by 2034, at a CAGR of 21.2% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Amgen, Genmab, Roche/Genentech, Ma",
    "url": "https://finnhub.io/api/news?id=72b1b717a0b8023b92ef414d0e6b32b7c767eef89d6ce78d4a8e2368c22b7281",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768379400,
      "headline": "[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
      "id": 138109921,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global T-Cell Engagers Market size & share revenue was valued at approximately USD 2.4 Billion in 2024 and is expected to reach USD 2.5 Billion in 2025 and is expected to reach around USD 18.8 Billion by 2034, at a CAGR of 21.2% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Amgen, Genmab, Roche/Genentech, Ma",
      "url": "https://finnhub.io/api/news?id=72b1b717a0b8023b92ef414d0e6b32b7c767eef89d6ce78d4a8e2368c22b7281"
    }
  }
]